RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)

NCT04567550 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

139

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Retinopathy (DR)
Center-Involved Diabetic Macular Edema (CI-DME)

Interventions

GENETIC: ABBV-RGX-314 Dose 1
GENETIC: ABBV-RGX-314 Dose 2
GENETIC: ABBV-RGX-314 Dose 3
DRUG: Topical Steroid
GENETIC: ABBV-RGX-314 Dose 4
BIOLOGICAL: Aflibercept

Sponsor

AbbVie

Collaborators

[object Object]